- Home
- KPRX vs ADXN Comparison
KPRX vs ADXN Comparison
Compare KPRX & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- ADXN
- Stock Information
- Founded
- KPRX 1998
- ADXN 2002
- Country
- KPRX United States
- ADXN Switzerland
- Employees
- KPRX N/A
- ADXN N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- KPRX Health Care
- ADXN Health Care
- Exchange
- KPRX Nasdaq
- ADXN Nasdaq
- Market Cap
- KPRX 10.0M
- ADXN 8.5M
- IPO Year
- KPRX N/A
- ADXN N/A
- Fundamental
- Price
- KPRX $3.26
- ADXN $7.79
- Analyst Decision
- KPRX Strong Buy
- ADXN Strong Buy
- Analyst Count
- KPRX 1
- ADXN 1
- Target Price
- KPRX $10.00
- ADXN $30.00
- AVG Volume (30 Days)
- KPRX 34.9K
- ADXN 45.6K
- Earning Date
- KPRX 11-08-2024
- ADXN 11-22-2024
- Dividend Yield
- KPRX N/A
- ADXN N/A
- EPS Growth
- KPRX N/A
- ADXN N/A
- EPS
- KPRX 1.69
- ADXN 0.06
- Revenue
- KPRX $16,020,000.00
- ADXN $701,260.00
- Revenue This Year
- KPRX N/A
- ADXN N/A
- Revenue Next Year
- KPRX N/A
- ADXN N/A
- P/E Ratio
- KPRX $2.04
- ADXN $1.05
- Revenue Growth
- KPRX N/A
- ADXN N/A
- 52 Week Low
- KPRX $3.00
- ADXN $5.39
- 52 Week High
- KPRX $8.98
- ADXN $27.90
- Technical
- Relative Strength Index (RSI)
- KPRX 43.44
- ADXN 42.74
- Support Level
- KPRX $3.30
- ADXN $7.14
- Resistance Level
- KPRX $4.04
- ADXN $8.40
- Average True Range (ATR)
- KPRX 0.28
- ADXN 0.62
- MACD
- KPRX -0.01
- ADXN 0.07
- Stochastic Oscillator
- KPRX 7.14
- ADXN 27.39
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.